Mito-FLAG as Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia

Publisher： Karger

E-ISSN： 2296-5262|24|4|356-360

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.24, Iss.4, 2001-09, pp. : 356-360

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 93, Iss. 3, 2018-03 ,pp. : 401-407

John Wiley & Sons Inc

Access to resources Recommend Favorite

Gemtuzumab Ozogamicin (Mylotarg®) in Children with Refractory or Relapsed Acute Myeloid Leukemia

By  

Oncology Research and Treatment, Vol. 27, Iss. 3, 2004-07 ,pp. : 269-272

Karger

Access to resources Recommend Favorite

Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia

By  

CANCER, Vol. 124, Iss. 2, 2018-01 ,pp. : 325-334

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Combination of Fludarabine, Cytarabine and Etoposide Is an Active and Well-Tolerated Regimen in Relapsed/Refractory Acute Myeloid Leukemia

By  

Acta Haematologica, Vol. 131, Iss. 4, 2013-11 ,pp. : 202-207

Karger

Access to resources Recommend Favorite

Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 7, 2015-07 ,pp. : E134-E135

John Wiley & Sons Inc

Access to resources Recommend Favorite